1. Pink Sheet
  2. >>Market Access

Ogsiveo And Winrevair Among Latest Orphan Drugs To Secure Early Access Funding In France

 
• By Francesca Bruce

HAS, the French health technology assessment body, has issued positive recommendations for several orphan drugs, including for Vyloy, which was provisionally rejected for reimbursement in the UK last year.

Several orphan drugs will receive swifter reimbursement through France's early access mechanism
Key Takeaways
  • SpingWorks Therapeutics Ogsiveo for treating desmoid tumors has secured a recommendation for reimbursement in France before it receives marketing authorization through the country’s early access mechanism.
  • MSD’s Winrevair, the first activin signaling inhibitor therapy approved to treat pulmonary hypertension, has received a positive recommendation for early reimbursement.
  • French authorities have also recommended early reimbursement for Astellas’ Vyloy for treating gastric or gastroesophageal junction adenocarcinoma.

Ogsiveo, (nirogacestat), SpringWorks Therapeutics treatment for desmoid tumors, and Winrevair (sotatercept), MSD’s treatment for pulmonary arterial hypertension (PAH), are among the latest orphan drugs to be recommended for reimbursement in...

Ogsiveo received its recommendation from HAS, the French health technology assessment (HTA) body, before securing EU marketing approval. Winrevair, meanwhile, was approved in the EU last August.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Health Technology Assessment

More from Geography

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.

ICH Targets RWE, Rare Diseases, Biosimilars, ATMPs In New Guideline Push

 
• By Vibha Sharma

The International Council for Harmonisation has identified four new topics that can benefit from global regulatory alignment, with timelines for initiating work to be determined later.